Asthma Clinical Trial
Official title:
Retrospective Review on Patients With Recurrent Asthmatic Attacks Requiring Hospitalizations
Asthma is a common respiratory disease. around the world. Asthma exacerbation is one of the major sequelae and associated with various morbidity and mortality. A satisfactory asthma control can help to bring down the risk of exacerbation and hence hospitalization. However, the real-world evidence on the clinical factors that leads to multiple admissions, when compared with single admission, due to asthma exacerbation is scarce. This study aimed at evaluating the clinical characteristics of patients who had single and multiple hospitalizations for asthma exacerbations, and exploring the risk factors that predict multiple hospitalizations.
Asthma is a common respiratory disease worldwide and in Hong Kong. According to the
estimation by the Center for Disease Control and Prevention in 2015, 7.6% adults in the
United States have asthma. In Hong Kong, the prevalence of asthma was estimated to be 10.1%
among 13 to 14 years old children and 5.8% in randomly selected Chinese elderly aged more
than 70. The clinical characteristics varies in different age groups, with elderly asthmatics
have higher rates of bronchial hyper-reactivity and more severe phenotypes, when comparing
with younger patients. This is more important in an ageing population.
Asthmatic exacerbation is not an uncommon complication and can be fatal. For those patients
with near-fatal asthma exacerbation, ICU admission and mechanical ventilation may be
necessary to prevent mortality. This is more common among poor controllers and adults.
Asthma-related deaths may be reduced if risk factors are recognized and addressed early.
Many predictors for exacerbation had been identified, both endogenous and exogenous,
including high eosinophil count, upper airway diseases, gastroesophageal reflux, poor inhaler
technique, medication non-compliance, guideline non-compliance. One of the most powerful
predictors for future exacerbation in patients with severe or difficult-to-treat asthma is a
recent severe asthma exacerbation. In addition, hospitalization for exacerbations requiring
ICU care and mechanical ventilation are both predictors for near-fatal asthma. After the
acute attack, its unfavourable impact continues and can lead to multiple sequelae.
Exacerbation of asthma is associated with a more rapid decline in the post-bronchodilator
forced expiratory volume in 1 second and worse quality of life. In addition, individuals with
uncontrolled asthma had higher medical expenditures and decreased productivity, contributing
to a greater economic burden when compared with individuals without asthma. In contrary,
patients with controlled asthma had lower hospitalization rate, mortality rate and less
decline in lung function.
Many of these factors are potentially reversible. But, there is still a significant
proportion of asthma patients experiencing recurrent exacerbation despite optimization of
pharmacological treatment. A model of better asthma care may be established by improving the
understanding on these risk factors, leading to less exacerbation events.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|